Dermatological research and distribution company SkinMed has released SkinVital Retimitate A.C.E, a new serum that aims to stimulate fibroblast activity to increase collagen, control pigmentation and improve the efficiency of skin cells.
The company explains that the serum is a result of a 10-year research programme to develop the Retimitate molecule, an active molecule-like retinoic acid that was specifically designed to be an advancement of other retinoids, but with fewer side effects.
Managing director and head trainer at SkinMed, Peter Roberts, said, “The Retimitate molecule is supported by the antioxidant properties of vitamin C and vitamin E, which potentiates the activity of the retinoid. The other associated ingredients in the serum are powerful antioxidants and boost absorption characteristics which also increases its ‘vitamin A’ activity.”
He explained that the launch strength is 1.5% and is comparable in efficacy to the ranges of retinoic acid strengths available ranging from 0.1%, 0.25%, 0.5% to 1%.
“Due to the safety profile we have more flexibility in increasing the frequency of dosing and we see this as the core benefit,” he added.